| Bioactivity | Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life[1][2][3]. |
| Invitro | Isecarosmab 结合 ADAMTS-5，但不结合 ADAMTS-1、ADAMTS-4 和 ADAMTS-15[1]。Isecarosmab (1-100 nM，5 天) 在受到促炎刺激的牛和 OA 人软骨外植体中降低 huARGS、exAGNxI 和 GAG 水平[1]。Isecarosmab (24-72 h) 阻断 ADAMTS-5 介导的 DCS TLR2 激活[2]。 |
| In Vivo | Isecarosmab (0.1-10 mg/kg，皮下注射，每三天一次) 减轻内侧半月板 (DMM) 切除小鼠的内侧软骨退化[1]。 |
| Name | Isecarosmab |
| CAS | 2254082-79-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Siebuhr AS, et al. The Anti-ADAMTS-5 Nanobody® M6495 Protects Cartilage Degradation Ex Vivo. Int J Mol Sci. 2020 Aug 20;21(17):5992. [2]. Sharma N, et al. Inflammation and joint destruction may be linked to the generation of cartilage metabolites of ADAMTS-5 through activation of toll-like receptors. Osteoarthritis Cartilage. 2020 May;28(5):658-668. [3]. C. Brenneis. Structural and symptomatic benefit of a half-live extended, systemically applied anti-ADAMTS-5 inhibitor (M6495). 2018. 26 (1), S299-S300. |